Electra Therapeutics' IPO

Q: When does the lock-up end?

Electra Therapeutics' IPO lock-up ends Mar 16, 2027. Its final prospectus says: “.”

Listed Sep 18, 2026 at $15 on Nasdaq as ETRA.

Offer price

$15

Market cap

$942M

23,333,334

Today 44% below its $15 offer price; its first day closed -11.7%.

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See ETRA ranked, live

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed Sep 18, 2026.

What does Electra Therapeutics do?

“We are a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.”

From its final prospectus (424B4), filed Sep 18, 2026

Electra Therapeutics' facts, each with its source
Fact	Electra Therapeutics
Incorporated	Delaware, 2018From its final prospectus (424B4) of Sep 18, 2026
Headquarters	South San Francisco, CaliforniaFrom its final prospectus (424B4) of Sep 18, 2026
Employees	46, as of June 30, 2026From its final prospectus (424B4) of Sep 18, 2026
Website	electra-therapeutics.comFrom its final prospectus (424B4) of Sep 18, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Electra Therapeutics' facts, each with its source
Fact	Electra Therapeutics
Shares offered	23,333,334From the final prospectus (424B4) filed Sep 18, 2026
Offer price	$15 a shareFrom the final prospectus (424B4) filed Sep 18, 2026
Raised at that price	$350 millionFrom the final prospectus (424B4) filed Sep 18, 2026
Underwriters' discount	$24.5 millionFrom the final prospectus (424B4) filed Sep 18, 2026
Underwriters' option	3,500,000 more sharesFrom the final prospectus (424B4) filed Sep 18, 2026
Underwriters	Jefferies, TD Cowen, Evercore ISI, and CantorFrom the final prospectus (424B4) filed Sep 18, 2026, as its cover names them
Exchange	Nasdaq Global Select Market, as ETRAFrom the final prospectus (424B4) filed Sep 18, 2026
Shares outstanding after	62,766,955From the final prospectus (424B4) filed Sep 18, 2026
Market cap at the offer price	$942 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Electra Therapeutics' facts, each with its source
Fact	Electra Therapeutics
Revenue	None from product sales yetFrom its final prospectus (424B4) of Sep 18, 2026: it has not generated any revenue
Net loss	$62 million, year to December 31, 2025From its final prospectus (424B4) of Sep 18, 2026, its summary financial data
Cash	$97.7 million, as of June 30, 2026From its final prospectus (424B4) of Sep 18, 2026: cash, cash equivalents and marketable securities
Last preferred stock	Series C preferredFrom its final prospectus (424B4) of Sep 18, 2026

What risks does Electra Therapeutics name first?

“We have a limited operating history and have no products approved for commercial sale, which may make it difficult for investors to evaluate our business, likelihood of success, and viability.”
“We have incurred significant operating losses since our inception and have not generated any revenue.”
“Even if this offering is successful, we will require substantial additional capital to finance our operations and achieve our goals.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Electra Therapeutics' IPO

Electra Therapeutics' IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Aug 28, 2026	Form S-1, SEC EDGAR
Declared effective by the SECSEC notice of effectiveness, SEC EDGAR	Sep 17, 2026	SEC notice of effectiveness, SEC EDGAR
Pricedfinal prospectus (424B4), filed Sep 18, SEC EDGAR	Sep 17, 2026	final prospectus (424B4), filed Sep 18, SEC EDGAR
Exchange registration filedexchange registration (Form 8-A), SEC EDGAR	Sep 18, 2026	exchange registration (Form 8-A), SEC EDGAR
First tradeMassive's IPO calendar	Sep 18, 2026	Massive's IPO calendar
Lock-up endsfinal prospectus, SEC EDGAR: “”	Mar 16, 2027	final prospectus, SEC EDGAR: “”

How did its first days trade?

From its daily bars, each close against its $15 offer price.

Electra Therapeutics' first sessions
Day	Open	Close	From the offer
Sep 18	$15	$13.25	-11.7%
Sep 21	$13.94	$13.92	-7.2%
Sep 22	$13.88	$13.62	-9.2%
Sep 23	$13.56	$12.67	-15.5%
Sep 24	$12.54	$11.82	-21.2%

What is Electra Therapeutics' Quality Score?

-1

Poor

27 trading days so far; 5 of the 14 checks wait for more history.

ETRA's page, with every reason behind its score

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
OPAYNYSE: OPAY · No day yet	$19 to $21	Not yet	No day yetexchange registration Oct 26
Georgia BankingNasdaq: GBC · No day yet	Direct	Not yet	No day yetexchange registration Oct 21
Aspen NeuroscienceNasdaq: ASPE · No day yet	$15 to $17About $465M	$465Mat the midpoint	No day yetterms set Oct 26
Bambusa TherapeuticsNasdaq: BBTX · No day yet	$15 to $17About $796M	$796Mat the midpoint	No day yetterms set Oct 26
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetterms set Oct 26
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26

Electra Therapeutics IPO questions

When is Electra Therapeutics' IPO?

Listed Sep 18, 2026 at $15 on Nasdaq as ETRA.

What is Electra Therapeutics' IPO price?

Electra Therapeutics' IPO priced at $15 a share, per its final prospectus of Sep 18, 2026.

How many shares is Electra Therapeutics selling?

23,333,334 shares, and the underwriters may buy 3,500,000 more, per its final prospectus (424B4).

Who are the underwriters?

Jefferies, TD Cowen, Evercore ISI, and Cantor, as the prospectus's cover names them.

When does the lock-up end?

Electra Therapeutics' IPO lock-⁠up ends Mar 16, 2027. Its final prospectus says: “.”

Does Breakaway rate Electra Therapeutics?

Electra Therapeutics has a Quality Score of -1 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Electra Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and September 2026's listings.